Quick Answer
Ensysce Biosciences, Inc. reported Total Assets of $7.45 million for the year ending 2025.
- Ensysce Biosciences, Inc. showed an increase of +33.1% in Total Assets from 2024 to 2025.
- This data is from Ensysce Biosciences, Inc.'s annual report (Form 10-K), filed with the SEC on March 30, 2026.
- XBRL data for this metric is available from 2017 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2017: $400.0 thousand | Q1 2018: $202.87 million | Q2 2018: $203.23 million | Q3 2018: $204.03 million | Q1 2019: $205.56 million | Q2 2019: $206.36 million | Q3 2019: $207.21 million | Q1 2020: $61.60 million | Q2 2020: $13.41 million | Q3 2020: $13.29 million | Q1 2021: $12.98 million | Q2 2021: $9.20 million | Q3 2021: $9.72 million | Q1 2022: $12.37 million | Q2 2022: $7.95 million | Q3 2022: $8.29 million | Q1 2023: $3.91 million | Q2 2023: $6.36 million | Q3 2023: $3.22 million | Q1 2024: $5.07 million | Q2 2024: $2.80 million | Q3 2024: $9.38 million | Q1 2025: $4.61 million | Q2 2025: $5.57 million | Q3 2025: $3.18 million.
- Over the full 9 years of available data (2017 to 2025), Ensysce Biosciences, Inc.'s Total Assets has declined by 96.3%.
- Historical annual values: Fiscal year 2025: $7.45 million | Fiscal year 2024: $5.60 million | Fiscal year 2023: $2.71 million | Fiscal year 2022: $5.89 million | Fiscal year 2021: $16.42 million | Fiscal year 2020: $351.8 thousand | Fiscal year 2019: $196.51 million | Fiscal year 2018: $204.83 million | Fiscal year 2017: $202.43 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: